Computer Vision Syndrome: Causes, Prevention, and Management

Kahal F, Al Darra A, Torbey A. Computer vision syndrome: a comprehensive literature review. Future Sci OA. 2025 Dec;11(1):2476923. doi: 10.1080/20565623.2025.2476923. Epub 2025 Mar 8. PMID: 40055942; PMCID: PMC11901492.

https://pmc.ncbi.nlm.nih.gov/articles/PMC11901492/pdf/IFSO_11_2476923.pdf

Influence of age and race on axial elongation in myopic children

Brennan, Noel A. MScOptom, PhD, FAAO1∗; Shamp, Wright PhD1; Maynes, Elizabeth MA, MD2; Cheng, Xu MD, PhD1; Bullimore, Mark A. MCOptom, PhD, FAAO3. Influence of age and race on axial elongation in myopic children: A systematic review and meta-regression. Optometry and Vision Science 101(8):p 497-507, August 2024. | DOI: 10.1097/OPX.0000000000002176

Axial length targets for myopia control

Chamberlain P, Lazon de la Jara P, Arumugam B, Bullimore MA. Axial length targets for myopia control. Ophthalmic Physiol Opt. 2021 May;41(3):523-531. doi: 10.1111/opo.12812. Epub 2021 May 5. PMID: 33951213; PMCID: PMC8252804.

https://pmc.ncbi.nlm.nih.gov/articles/PMC8252804/pdf/OPO-41-523.pdf

The Association Between Refraction, Ocular Biometry, and a Child’s Behavior Assessed by Conners’ Parental Rating Scale

Cohen Y, Eidel M, Greenberger Y, Vidan A, Chassid O. The Association Between Refraction, Ocular Biometry, and a Child’s Behavior Assessed by Conners’ Parental Rating Scale. Clin Ophthalmol. 2025;19:1183-1190. https://doi.org/10.2147/OPTH.S513759

https://www.dovepress.com/article/download/101694

Visual Field Progression in the Ocular Hypertension Treatment Study

Gordon MO, Heuer DK, Higginbotham EJ, Parrish RK, Liu L, Brandt JD, Huecker JB, Miller JP, Perera C, Xie C, Keltner JL, Johnson CA, Gardiner SK, Liebmann JM, Kass MA. Visual Field Progression in the Ocular Hypertension Treatment Study. Am J Ophthalmol. 2025 Mar;271:360-370. doi: 10.1016/j.ajo.2024.11.017. Epub 2024 Dec 6. PMID: 39647569.

https://www.ajo.com/action/showPdf?pii=S0002-9394%2824%2900545-2

Myopia control efficacy of spectacle lenses with highly aspherical lenslets: results of a 5-year follow-up study

Li, X., Huang, Y., Liu, C. et al. Myopia control efficacy of spectacle lenses with highly aspherical lenslets: results of a 5-year follow-up study. Eye and Vis 12, 10 (2025). https://doi.org/10.1186/s40662-025-00427-3https://eandv.biomedcentral.com/counter/pdf/10.1186/s40662-025-00427-3.pdf

Smartwatch Measures of Outdoor Exposure and Myopia in Children

Chen J, Wang J, Qi Z, Liu S, Zhao L, Zhang B, Dong K, Du L, Yang J, Zou H, He X, Xu X. Smartwatch Measures of Outdoor Exposure and Myopia in Children. JAMA Netw Open. 2024 Aug 1;7(8):e2424595. doi: 10.1001/jamanetworkopen.2024.24595. PMID: 39136948; PMCID: PMC11322842.

https://jamanetwork.com/journals/jamanetworkopen/articlepdf/2822298/chen_2024_oi_240770_1722953028.31308.pdf

Digital Screen Time and Myopiahttps://jamanetwork.com/journals/jamanetworkopen/articlepdf/2830598/ha_2025_oi_241676_1739481438.70977.pdf

Ha A, Lee YJ, Lee M, Shim SR, Kim YK. Digital Screen Time and Myopia: A Systematic Review and Dose-Response Meta-Analysis. JAMA Netw Open. 2025 Feb 3;8(2):e2460026. doi: 10.1001/jamanetworkopen.2024.60026. PMID: 39982728; PMCID: PMC11846013.

Central serous chorioretinopathy: An evidence-based treatment guideline

Feenstra HMA, van Dijk EHC, Cheung CMG, Ohno-Matsui K, Lai TYY, Koizumi H, Larsen M, Querques G, Downes SM, Yzer S, Breazzano MP, Subhi Y, Tadayoni R, Priglinger SG, Pauleikhoff LJB, Lange CAK, Loewenstein A, Diederen RMH, Schlingemann RO, Hoyng CB, Chhablani JK, Holz FG, Sivaprasad S, Lotery AJ, Yannuzzi LA, Freund KB, Boon CJF. Central serous chorioretinopathy: An evidence-based treatment guideline. Prog Retin Eye Res. 2024 Jul;101:101236. doi: 10.1016/j.preteyeres.2024.101236. Epub 2024 Feb 1. PMID: 38301969.

https://www.sciencedirect.com/science/article/pii/S1350946224000016/pdfft?md5=ad36b9e0851c96c3a0f3082dbeed1d93&pid=1-s2.0-S1350946224000016-main.pdf

Neuro-ophthalmic evaluation and management of pituitary disease

Wang, M.T.M., Meyer, J.A. & Danesh-Meyer, H.V. Neuro-ophthalmic evaluation and management of pituitary disease. Eye 38, 2279–2288 (2024). https://doi.org/10.1038/s41433-024-03187-x

https://www.nature.com/articles/s41433-024-03187-x.pdf